427 related articles for article (PubMed ID: 18691983)
1. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
Lieberman-Blum SS; Fung HB; Bandres JC
Clin Ther; 2008 Jul; 30(7):1228-50. PubMed ID: 18691983
[TBL] [Abstract][Full Text] [Related]
2. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
Perry CM
Drugs; 2010 Jun; 70(9):1189-213. PubMed ID: 20518583
[TBL] [Abstract][Full Text] [Related]
3. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.
Yost R; Pasquale TR; Sahloff EG
Am J Health Syst Pharm; 2009 Apr; 66(8):715-26. PubMed ID: 19336831
[TBL] [Abstract][Full Text] [Related]
4. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
Cooper DA; Heera J; Goodrich J; Tawadrous M; Saag M; Dejesus E; Clumeck N; Walmsley S; Ting N; Coakley E; Reeves JD; Reyes-Teran G; Westby M; Van Der Ryst E; Ive P; Mohapi L; Mingrone H; Horban A; Hackman F; Sullivan J; Mayer H
J Infect Dis; 2010 Mar; 201(6):803-13. PubMed ID: 20151839
[TBL] [Abstract][Full Text] [Related]
5. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
[TBL] [Abstract][Full Text] [Related]
6. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
Ndegwa S
Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
[TBL] [Abstract][Full Text] [Related]
7. Maraviroc.
Carter NJ; Keating GM
Drugs; 2007; 67(15):2277-88; discussion 2289-90. PubMed ID: 17927288
[TBL] [Abstract][Full Text] [Related]
8. [Maraviroc efficacy in clinical studies on the development of the molecule].
Moreno S; Hernández B; Gutiérrez C; Delsol E
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():17-22. PubMed ID: 19133217
[TBL] [Abstract][Full Text] [Related]
9. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
Bredeek UF; Harbour MJ
Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724
[TBL] [Abstract][Full Text] [Related]
10. Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors.
Ruiz-Mateos E; González-Serna A; Genebat M; Machmach K; Vidal F; Muñoz-Fernández A; Ferrando-Martinez S; Leal M
Antimicrob Agents Chemother; 2011 Oct; 55(10):4664-9. PubMed ID: 21807977
[TBL] [Abstract][Full Text] [Related]
11. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
Emmelkamp JM; Rockstroh JK
Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
[TBL] [Abstract][Full Text] [Related]
12. Maraviroc: a new CCR5 antagonist.
Sayana S; Khanlou H
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.
Rosario MC; Jacqmin P; Dorr P; James I; Jenkins TM; Abel S; van der Ryst E
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):86-94. PubMed ID: 18333870
[TBL] [Abstract][Full Text] [Related]
14. Maraviroc.
Fadel H; Temesgen Z
Drugs Today (Barc); 2007 Nov; 43(11):749-58. PubMed ID: 18174962
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of maraviroc.
Parra J; Portilla J; Pulido F; Sánchez-de la Rosa R; Alonso-Villaverde C; Berenguer J; Blanco JL; Domingo P; Dronda F; Galera C; Gutiérrez F; Kindelán JM; Knobel H; Leal M; López-Aldeguer J; Mariño A; Miralles C; Moltó J; Ortega E; Oteo JA
Clin Drug Investig; 2011; 31(8):527-542. PubMed ID: 21595497
[TBL] [Abstract][Full Text] [Related]
16. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
Hardy WD; Gulick RM; Mayer H; Fätkenheuer G; Nelson M; Heera J; Rajicic N; Goodrich J
J Acquir Immune Defic Syndr; 2010 Dec; 55(5):558-64. PubMed ID: 20703158
[TBL] [Abstract][Full Text] [Related]
17. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
[TBL] [Abstract][Full Text] [Related]
18. [Clinical pharmacokinetic of maraviroc].
Peytavin G
Med Mal Infect; 2008 Mar; 38 Suppl 1():S12-6. PubMed ID: 18455057
[TBL] [Abstract][Full Text] [Related]
19. Maraviroc: a review of its use in HIV infection and beyond.
Woollard SM; Kanmogne GD
Drug Des Devel Ther; 2015; 9():5447-68. PubMed ID: 26491256
[TBL] [Abstract][Full Text] [Related]
20. Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection.
Caldwell DJ; Evans JD
Expert Opin Pharmacother; 2008 Dec; 9(18):3231-42. PubMed ID: 19040343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
